BioForce director reports 1M-share stock stake

New director Scott Mager reports initial ownership of 1,000,000 restricted BFNH common shares received instead of cash pay under a three‑year service agreement.

Rhea-AI Filing Summary

BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) reported the initial equity holdings of director Scott Mager on a Form 3. He holds 1,000,000 shares of common stock, received as restricted shares in lieu of cash compensation under a three‑year service contract with the company. No Rule 10b5‑1 trading plan is reported.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mager Scott

Role Director

Type	Security	Shares	Price	Value
holding	Common Stock; Par Value $0.001 F1	--	--	--

Holdings After Transaction: Common Stock; Par Value $0.001 — 1,000,000 shares (Direct)

Footnotes (1)

1. F1. Reporting Person received restricted shares in lieu of cash compensation based on a (3) three service contract with the Company.

Key Figures

Common shares beneficially owned: 1,000,000 shares Par value per common share: $0.001 per share Service contract term: 3 years

3 metrics

Common shares beneficially owned 1,000,000 shares Direct holdings of Scott Mager reported on Form 3

Par value per common share $0.001 per share Par value of BIOFORCE NANOSCIENCES HOLDINGS, INC. common stock

Service contract term 3 years Restricted shares received in lieu of cash compensation based on a three‑year service contract

Key Terms

restricted shares, cash compensation, par value

3 terms

restricted shares financial

"Reporting Person received restricted shares in lieu of cash compensation"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

cash compensation financial

"received restricted shares in lieu of cash compensation based on a (3) three service contract"

par value financial

"Common Stock; Par Value $0.001"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing disclose about BFNH director Scott Mager?

The Form 3 shows that director Scott Mager beneficially owns 1,000,000 shares of BFNH common stock, held directly as restricted shares received instead of cash compensation under a three‑year service contract with BIOFORCE NANOSCIENCES HOLDINGS, INC.

How many BFNH shares does Scott Mager beneficially own according to the Form 3?

Scott Mager beneficially owns 1,000,000 shares of BFNH common stock, held directly. These are reported as restricted shares received as compensation under a three‑year service agreement with BIOFORCE NANOSCIENCES HOLDINGS, INC.

What type of BFNH security does Scott Mager hold and what is its par value?

Scott Mager holds common stock of BIOFORCE NANOSCIENCES HOLDINGS, INC. with a stated par value of $0.001 per share, reported as restricted shares received instead of cash compensation.

How did Scott Mager receive his 1,000,000 BFNH shares?

According to the footnote, Scott Mager received restricted shares of BFNH common stock in lieu of cash compensation, based on a three‑year service contract with BIOFORCE NANOSCIENCES HOLDINGS, INC.

Does the Scott Mager Form 3 for BFNH report any stock purchases or sales?

No. The Form 3 is an initial ownership report and lists 1,000,000 restricted shares of BFNH common stock held directly. It does not report any purchase or sale transactions and no Rule 10b5‑1 trading plan is mentioned.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 04:05 PM EDT Accepted by SEC EDGAR 09/03/2026 - 04:04 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mager Scott

(Last) (First) (Middle)

2719 HOLLYWOOD BLVD.

SECOND FLOOR

(Street)

HOLLYWOOD FLORIDA 33020

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/31/2026

3. Issuer Name and Ticker or Trading Symbol
BIOFORCE NANOSCIENCES HOLDINGS, INC. [ BFNH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock; Par Value $0.001	1,000,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting Person received restricted shares in lieu of cash compensation based on a (3) three service contract with the Company.

	/s/ Scott Mager	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)